U.S. markets close in 2 hours 13 minutes

T2 Biosystems, Inc. (TTOO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.9851-0.0249 (-2.47%)
As of 1:45PM EDT. Market open.

T2 Biosystems, Inc.

101 Hartwell Avenue
Lexington, MA 02421
United States
781 761 4646

IndustryDiagnostics & Research
Full Time Employees148

Key Executives

NameTitlePayExercisedYear Born
Mr. John J. Sperzel III, B.Sc.Chairman & CEO897.27kN/A1963
Mr. Alec J. BarclayChief Operations Officer575.55kN/A1980
Mr. Anthony P. PareChief Commercial Officer513.25kN/A1963
Mr. John M. Sprague CPAChief Financial OfficerN/AN/A1958
Mr. Michael Terrence GibbsVP & Gen. CounselN/AN/A1971
Ms. Kelley J. MorganChief People OfficerN/AN/A1976
Dr. Aparna Jha Ahuja M.D.Chief Medical OfficerN/AN/A1967
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Corporate Governance

T2 Biosystems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.